The 21st annual meeting of the International Myeloma Society takes place September 25-28, 2024, in Rio de Janiero, Brazil.

The Food and Drug Administration (FDA) has approved Sarclisa ® (isatuximab-irfc) in combination with bortezomib, lenalidomide and dexamethasone (VRd) for the treatment of patients with newly diagnosed ...

Blood cancers account for about 10 percent of new cancer cases each year. While the cause for most is unknown, research and treatments are improving rapidly.

This latest FDA decision marks the first approval for SNY's Sarclisa as a first-line treatment for multiple myeloma patients.

LADENBURG, Germany - () - September 23, 2024 - Heidelberg Pharma AG (FSE: HPHA), a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), today announces that new data from its ...

In addition to other MM indications, Isatuximab's anti-CD38 competitor on the US market, daratumumab (Darzalex — Johnson & Johnson), also carries a first-line indication for transplant-ineligible MM ...

In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma(MM) who have received at least one prior therapy; and in combination with dexamethasone for ...

Global real-world data support the use of autologous hematopoietic stem cell transplant in patients with newly diagnosed multiple myeloma, according to researchers.

XPOVIO® is the first and only approved XPO1 inhibitor in Thailand. XPOVIO® has been approved for multiple indications in nine markets across the APAC region. Antengene has submitted a new drug applica ...

Barely a week after Bruce Springsteen and the E Street Band delivered an already legendary live set beside the Atlantic Ocean ...

Patients will have access to TGH and MGB providers for radiation oncology, medical imaging, and clinical oncology.

New York State confirmed its first case of mosquito-borne eastern equine encephalitis in close to a decade. (ABC News) ...